The impact of individual clinical features in cold agglutinin disease: hemolytic versus non-hemolytic symptoms

References

• Schubothe H. The cold hemagglutinin disease. Semin Hematol. 1966;3(1):27–47.
   PubMedGoogle Scholar
• Berentsen S, Barcellini W, D’Sa S, et al. Cold agglutinin disease revisited: a multinational, observational study of 232 patients. Blood. 2020;136(4):480–488. doi: 10.1182/blood.2020005674
   PubMed Web of Science ®Google Scholar
• Swiecicki PL, Hegerova LT, Gertz MA. Cold agglutinin disease. Blood. 2013;122(7):1114–1121. doi: 10.1182/blood-2013-02-474437
   PubMed Web of Science ®Google Scholar
• Ulvestad E, Berentsen S, Bø K, et al. Clinical immunology of chronic cold agglutinin disease. Eur J Haematol. 1999;63(4):259–266. doi: 10.1111/j.1600-0609.1999.tb01887.x
   PubMed Web of Science ®Google Scholar
• Randen U, Trøen G, Tierens A, et al. Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma. Haematologica. 2014;99(3):497–504. doi: 10.3324/haematol.2013.091702
   PubMed Web of Science ®Google Scholar
• Naresh KN, Rossi D, Chen X, et al. Cold agglutinin disease. In: WHO classification of haematolymphoid tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2022. p. 349. Available from: https://tumourclassification.iarc.who.int/chaptercontent/363/349
   Google Scholar
• Guenther A, Tierens A, Malecka A, et al. The histopathology of cold agglutinin disease-associated B-Cell lymphoproliferative disease. Am J Clin Pathol. 2023;160(3):229–237. doi: 10.1093/ajcp/aqad048
   PubMed Web of Science ®Google Scholar
• Winter O, Dame C, Jundt F, et al. Pathogenic long-lived plasma cells and their survival niches in autoimmunity, malignancy, and allergy. J Immunol. 2012;189(11):5105–5111. doi: 10.4049/jimmunol.1202317
   PubMed Web of Science ®Google Scholar
• Jonsen J, Kåss E. Investigations on complement and complement components in a case of high-titer cold hemagglutination. Acta Med Scand. 1959;165(3):229–233. doi: 10.1111/j.0954-6820.1959.tb14494.x
   PubMedGoogle Scholar
• Berentsen S, D’Sa S, Randen U, et al. Cold agglutinin disease: Improved understanding of pathogenesis helps define targets for therapy. Hemato. 2022;3(1):574–594. doi: 10.3390/hemato3040040
   Google Scholar
• Hill QA, Hill A, Berentsen S. Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment. Blood Adv. 2019;3(12):1897–1906. doi: 10.1182/bloodadvances.2019000036
   PubMed Web of Science ®Google Scholar
• Jäger U, Barcellini W, Broome CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the first international consensus meeting. Blood Rev. 2020;41(1):100648. doi: 10.1016/j.blre.2019.100648
   PubMedGoogle Scholar
• Berentsen S, Tjønnfjord GE. Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia. Blood Rev. 2012;26(3):107–115. doi: 10.1016/j.blre.2012.01.002
   PubMed Web of Science ®Google Scholar
• Zagorski E, Pawar T, Rahimian S, et al. Cold agglutinin autoimmune haemolytic anaemia associated with novel coronavirus (COVID-19). Br J Haematol. 2020;190(4):e183–e184. doi: 10.1111/bjh.16892
   PubMed Web of Science ®Google Scholar
• Crisp D, Pruzanski W. B-cell neoplasms with homogeneous cold-reacting antibodies (cold agglutinins). Am J Med. 1982;72(6):915–922. doi: 10.1016/0002-9343(82)90852-x
   PubMed Web of Science ®Google Scholar
• Berentsen S. Cold agglutinin disease. Hematology Am Soc Hematol Educ Program. 2016;2016(1):226–231. doi: 10.1182/asheducation-2016.1.226
   PubMed Web of Science ®Google Scholar
• Hansen DL, Berentsen S, Fattizzo B, et al. Seasonal variation in the incidence of cold agglutinin disease in Norway, Denmark, and Italy. Am J Hematol. 2021;96(7):E262–E265. doi: 10.1002/ajh.26196
   PubMed Web of Science ®Google Scholar
• Berentsen S, Ulvestad E, Langholm R, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica. 2006;91(4):460–466.
   PubMed Web of Science ®Google Scholar
• Berentsen S. How I treat cold agglutinin disease. Blood. 2021;137(10):1295–1303. doi: 10.1182/blood.2019003809
   PubMed Web of Science ®Google Scholar
• Berentsen S, Fattizzo B, Barcellini W. The choice of new treatments in autoimmune hemolytic anemia: how to pick from the basket? Front Immunol. 2023;14:1180509. doi: 10.3389/fimmu.2023.1180509
   PubMed Web of Science ®Google Scholar
• Gelbenegger G, Berentsen S, Jilma B. Monoclonal antibodies for treatment of cold agglutinin disease. Expert Opin Biol Ther. 2023;23(5):395–406. doi: 10.1080/14712598.2023.2209265
   PubMed Web of Science ®Google Scholar
• Berentsen S, Barcellini W, Longo DL. Autoimmune Hemolytic Anemias. N Engl J Med. 2021;385(15):1407–1419. doi: 10.1056/NEJMra2033982
   PubMed Web of Science ®Google Scholar
• Gertz MA. Updates on the diagnosis and management of cold autoimmune hemolytic anemia. Hematol Oncol Clin North Am. 2022;36(2):341–352. doi: 10.1016/j.hoc.2021.11.001
   PubMed Web of Science ®Google Scholar
• Christenson WN, Dacie JV, Croucher BE, et al. Electrophoretic studies on sera containing high-titre cold haemagglutinins: identification of the antibody as the cause of an abnormal γ Peak. Br J Haematol. 1957;3(3):262–273. doi: 10.1111/j.1365-2141.1957.tb05795.x
   PubMed Web of Science ®Google Scholar
• Harboe M, van Furth R, Schubothe H, et al. Exclusive occurrence of K chains in isolated cold haemagglutinins. Scand J Haematol. 1965;2(3):259–266. doi: 10.1111/j.1600-0609.1965.tb01303.x
   PubMedGoogle Scholar
• Berentsen S, Bø K, Shammas FV, et al. Chronic cold agglutinin disease of the “idiopathic” type is a premalignant or low-grade malignant lymphoproliferative disease. APMIS. 1997;105(5):354–362. doi: 10.1111/j.1699-0463.1997.tb00581.x
   PubMed Web of Science ®Google Scholar
• Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–1748. doi: 10.1038/s41375-022-01620-2
   PubMed Web of Science ®Google Scholar
• Berentsen S, Röth A, Randen U, et al. Cold agglutinin disease: current challenges and further prospects. J Blood Med. 2019;10:93–103. doi: 10.2147/JBM.S177621
   PubMed Web of Science ®Google Scholar
• Dacie J. Auto-immune haemolytic anaemia (AIHA): cold-antibody syndromes II: immunochemistry and specificity of the antibodies; serum complement in autoimmune haemolytic anaemia. In: Dacie J, editor. The haemolytic anaemias. Vol. 3. London: Churchill Livingstone; 1992. p. 240–295.
   Google Scholar
• Arthold C, Skrabs C, Mitterbauer-Hohendanner G, et al. Cold antibody autoimmune hemolytic anemia and lymphoproliferative disorders: a retrospective study of 20 patients including clinical, hematological, and molecular findings. Wien Klin Wochenschr. 2014;126(11–12):376–382. doi: 10.1007/s00508-014-0547-z
   PubMed Web of Science ®Google Scholar
• Malecka A, Trøen G, Tierens A, et al. Immunoglobulin heavy and light chain gene features are correlated with primary cold agglutinin disease onset and activity. Haematologica. 2016;101(9):e361–e364. doi: 10.3324/haematol.2016.146126
   PubMed Web of Science ®Google Scholar
• Khwaja J, D’Sa S, Minnema MC, et al. IgM monoclonal gammopathies of clinical significance: diagnosis and management. Haematologica. 2022;107(9):2037–2050. doi: 10.3324/haematol.2022.280953
   PubMed Web of Science ®Google Scholar
• Malecka A, Trøen G, Delabie J, et al. The mutational landscape of cold agglutinin disease: CARD11 and CXCR4 mutations are correlated with lower hemoglobin levels. Am J Hematol. 2021;96(8):E279–E283. doi: 10.1002/ajh.26205
   PubMed Web of Science ®Google Scholar
• Malecka A, Trøen G, Tierens A, et al. Frequent somatic mutations of KMT2D (MLL2) and CARD11 genes in primary cold agglutinin disease. Br J Haematol. 2018;183(5):838–842. doi: 10.1111/bjh.15063
   PubMed Web of Science ®Google Scholar
• Malecka A, Delabie J, Østlie I, et al. Cold agglutinin–associated B-cell lymphoproliferative disease shows highly recurrent gains of chromosome 3 and 12 or 18. Blood Adv. 2020;4(6):993–996. doi: 10.1182/bloodadvances.2020001608
   PubMed Web of Science ®Google Scholar
• Malecka A, Østlie I, Trøen G, et al. Gene expression analysis revealed downregulation of complement receptor 1 in clonal B cells in cold agglutinin disease. Clinical And Experimental Immunology. 2023; online ahead of print. 216(1):45–54. doi: 10.1093/cei/uxad135
   Web of Science ®Google Scholar
• Issitt PD. I blood group system and its relationship to disease. J Med Lab Technol. 1968;25(1):1–6.
   PubMedGoogle Scholar
• Marsh WL. Anti-i: a cold antibody defining the Ii relationship in human red cells. Br J Haematol. 1961;7(1):200–209. doi: 10.1111/j.1365-2141.1961.tb00329.x
   PubMedGoogle Scholar
• Berentsen S. New insights in the pathogenesis and therapy of cold agglutinin-mediated autoimmune hemolytic anemia. Front Immunol. 2020;11:590. doi: 10.3389/fimmu.2020.00590
   PubMed Web of Science ®Google Scholar
• Rosse WF, Adams JP. The variability of hemolysis in the cold agglutinin syndrome. Blood. 1980;56(3):409–416. doi: 10.1182/blood.V56.3.409.409
   PubMed Web of Science ®Google Scholar
• Silberstein LE, Berkman EM, Schreiber AD. Cold hemagglutinin disease associated with IgG cold-reactive antibody. Ann Intern Med. 1987;106(2):238–242. doi: 10.7326/0003-4819-106-2-238
   PubMed Web of Science ®Google Scholar
• Pascual V, Victor K, Spellerberg M, et al. VH restriction among human cold agglutinins. The VH4-21 gene segment is required to encode anti-I and anti-i specificities. J Immunol. 1992;149(7):2337–2344. doi: 10.4049/jimmunol.149.7.2337
   PubMed Web of Science ®Google Scholar
• Potter KN, Hobby P, Klijn S, et al. Evidence for involvement of a hydrophobic patch in framework region 1 of human V4-34-encoded igs in recognition of the red blood cell I antigen. J Immunol. 2002;169(7):3777–3782. doi: 10.4049/jimmunol.169.7.3777
   PubMed Web of Science ®Google Scholar
• Li Y, Spellerberg MB, Stevenson FK, et al. The I binding specificity of human VH 4-34 (VH 4-21) encoded antibodies is determined by both VH framework region 1 and complementarity determining region 3. J Mol Biol. 1996;256(3):577–589. doi: 10.1006/jmbi.1996.0110
   PubMed Web of Science ®Google Scholar
• Paliwal S, Thakkar D, Chin WJ, et al. Selective targeting of pathogenic auto-reactive VH4–34 B cells with a rationally developed anti-VH4–34 antibody offers a new therapeutic approach for autoimmune disorders. J Immunol. 2023;210(1_Supplement):.238.20–.238.20. doi: 10.4049/jimmunol.210.Supp.238.20
   Web of Science ®Google Scholar
• Pascual V, Capra JD. VH4-21, a human VH gene segment overrepresented in the autoimmune repertoire. Arthritis Rheum. 1992;35(1):11–18. doi: 10.1002/art.1780350103
   PubMed Web of Science ®Google Scholar
• Kraj P, Friedman DF, Stevenson F, et al. Evidence for the overexpression of the VH4-34 (VH4.21) ig gene segment in the normal adult human peripheral blood B cell repertoire. J Immunol. 1995;154(12):6406–6420. doi: 10.4049/jimmunol.154.12.6406
   PubMed Web of Science ®Google Scholar
• Jain MD, Cabrerizo-Sanchez R, Karkouti K, et al. Seek and you shall find–but then what do you do? Cold agglutinins in cardiopulmonary bypass and a single-center experience with cold agglutinin screening before cardiac surgery. Transfus Med Rev. 2013;27(2):65–73. doi: 10.1016/j.tmrv.2012.12.001
   PubMed Web of Science ®Google Scholar
• Stone MJ, McElroy YG, Pestronk A, et al. Human monoclonal macroglobulins with antibody activity. Seminars In Oncology. 2003;30(2):318–324. doi: 10.1053/sonc.2003.50077
   PubMed Web of Science ®Google Scholar
• Jefferies LC, Carchidi CM, Silberstein LE. Naturally occurring anti-i/I cold agglutinins may be encoded by different VH3 genes as well as the VH4.21 gene segment. J Clin Invest. 1993;92(6):2821–2833. doi: 10.1172/JCI116902
   PubMed Web of Science ®Google Scholar
• Potter KN. Molecular characterization of cold agglutinins. Transfus Sci. 2000;22(1–2):113–119. doi: 10.1016/s0955-3886(00)00031-x
   PubMedGoogle Scholar
• Pugh-Bernard AE, Silverman GJ, Cappione AJ, et al. Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance. J Clin Invest. 2001;108(7):1061–1070. doi: 10.1172/JCI200112462
   PubMed Web of Science ®Google Scholar
• Jaffe CJ, Atkinson JP, Frank MM. The role of complement in the clearance of cold agglutinin-sensitized erythrocytes in man. J Clin Invest. 1976;58(4):942–949. doi: 10.1172/JCI108547
   PubMed Web of Science ®Google Scholar
• Heni M, Saur SJ. Blood clotting at room temperature in cold agglutinin disease. Blood. 2013;121(25):4975. doi: 10.1182/blood-2012-12-472324
   PubMed Web of Science ®Google Scholar
• Solanki DL, Blackburn BC. Spurious red blood cell parameters due to serum cold agglutinins: observations on Ortho ELT-8 cell counter. Am J Clin Pathol. 1985;83(2):218–222. doi: 10.1093/ajcp/83.2.218
   PubMed Web of Science ®Google Scholar
• Petrusic V, Zivkovic I, Stojanovic M, et al. Antigenic specificity and expression of a natural idiotope on human pentameric and hexameric IgM polymers. Immunol Res. 2011;51(1):97–107. doi: 10.1007/s12026-011-8236-8
   PubMed Web of Science ®Google Scholar
• Petrusic V, Zivkovic I, Stojanovic M, et al. Hexameric immunoglobulin M in humans: desired or unwanted? Med Hypotheses. 2011;77(6):959–961. doi: 10.1016/j.mehy.2011.08.018
   PubMed Web of Science ®Google Scholar
• Hughey CT, Brewer JW, Colosia AD, et al. Production of IgM hexamers by normal and autoimmune B cells: implications for the physiologic role of hexameric IgM. J Immunol. 1998;161(8):4091–4097. doi: 10.4049/jimmunol.161.8.4091
   PubMed Web of Science ®Google Scholar
• Pruzanski W, Faird N, Keystone E, et al. The influence of homogeneous cold agglutinins on polymorphonuclear and mononuclear phagocytes. Clin Immunol Immunopathol. 1975;4(2):277–285. doi: 10.1016/0090-1229(75)90063-X
   PubMedGoogle Scholar
• Dunstan RA, Simpson MB, Rosse WF. The presence of the Ii blood group system on human platelets. Am J Clin Pathol. 1984;82(1):74–77. doi: 10.1093/ajcp/82.1.74
   PubMed Web of Science ®Google Scholar
• Lee JH. Neutrophil aggregation on the peripheral blood smear in a patient with cold agglutinin disease. Ann Hematol. 2017;96(5):885–886. doi: 10.1007/s00277-017-2962-5
   PubMed Web of Science ®Google Scholar
• Berentsen S. Neutrophil aggregation on the peripheral blood smear in a patient with cold agglutinin disease. Ann Hematol. 2017;96(10):1767–1768. doi: 10.1007/s00277-017-3077-8
   PubMed Web of Science ®Google Scholar
• Gavriilaki E, Brodsky RA. Complementopathies and precision medicine. J Clin Invest. 2020;130(5):2152–2163. doi: 10.1172/JCI136094
   PubMed Web of Science ®Google Scholar
• Berentsen S, Hill A, Hill QA, et al. Novel insights into the treatment of complement-mediated hemolytic anemias. Ther Adv Hematol. 2019;10:2040620719873321. doi: 10.1177/2040620719873321
   Web of Science ®Google Scholar
• Shi J, Rose EL, Singh A, et al. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Blood. 2014;123(26):4015–4022. doi: 10.1182/blood-2014-02-556027
   PubMed Web of Science ®Google Scholar
• Berentsen S, Randen U, Tjønnfjord GE. Cold agglutinin-mediated autoimmune hemolytic anemia. Hematol Oncol Clin North Am. 2015;29(3):455–471. doi: 10.1016/j.hoc.2015.01.002
   PubMed Web of Science ®Google Scholar
• Berentsen S. Complement activation and inhibition in autoimmune hemolytic anemia: focus on cold agglutinin disease. Semin Hematol. 2018;55(3):141–149. doi: 10.1053/j.seminhematol.2018.04.002
   PubMed Web of Science ®Google Scholar
• Varela JC, Tomlinson S. Complement: an overview for the clinician. Hematol Oncol Clin North Am. 2015;29(3):409–427. doi: 10.1016/j.hoc.2015.02.001
   PubMed Web of Science ®Google Scholar
• Ulvestad E, Berentsen S, Mollnes TE. Acute phase haemolysis in chronic cold agglutinin disease. Scand J Immunol. 2001;54(1–2):239–242. doi: 10.1046/j.1365-3083.2001.00960.x
   PubMed Web of Science ®Google Scholar
• Mold C, Gewurz H, Du Clos TW. Regulation of complement activation by C-reactive protein. Immunopharmacology. 1999;42(1–3):23–30. doi: 10.1016/s0162-3109(99)00007-7
   PubMedGoogle Scholar
• Ahearn JM, Fearon DT. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv Immunol. 1989;46:183–219. doi: 10.1016/s0065-2776(08)60654-9
   PubMed Web of Science ®Google Scholar
• Iida K, Nussenzweig V. Functional properties of membrane-associated complement receptor CR1. J Immunol. 1983;130(4):1876–1880. doi: 10.4049/jimmunol.130.4.1876
   PubMed Web of Science ®Google Scholar
• Kremlitzka M, Polgar A, Fulop L, et al. Complement receptor type 1 (CR1, CD35) is a potent inhibitor of B-cell functions in rheumatoid arthritis patients. Int Immunol. 2013;25(1):25–33. doi: 10.1093/intimm/dxs090
   PubMed Web of Science ®Google Scholar
• Erdei A, Kovacs KG, Nagy-Balo Z, et al. New aspects in the regulation of human B cell functions by complement receptors CR1, CR2, CR3 and CR4. Immunol Lett. 2021;237:42–57. doi: 10.1016/j.imlet.2021.06.006
   PubMed Web of Science ®Google Scholar
• Broome CM, Cunningham JM, Mullins M, et al. Increased risk of thrombotic events in cold agglutinin disease: a 10-year retrospective analysis. Res Pract Thromb Haemost. 2020;4(4):628–635. doi: 10.1002/rth2.12333
   PubMed Web of Science ®Google Scholar
• Joly F, Schmitt LA, Watson PAM, et al. The burden of cold agglutinin disease on patients’ daily life: web-based cross-sectional survey of 50 American patients. JMIR Form Res. 2022;6(7):e34248. doi: 10.2196/34248
   PubMedGoogle Scholar
• Rørvik K. The syndrome of high-titre cold haemagglutination; a survey and a case report. Acta Med Scand. 1954;148(4):299–308. doi: 10.1111/j.0954-6820.1954.tb01722.x
   PubMedGoogle Scholar
• U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 4.0. 2009. Available from: https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
   Google Scholar
• Berentsen S, Randen U, Oksman M, et al. Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial. Blood. 2017;130(4):537–541. doi: 10.1182/blood-2017-04-778175
   PubMed Web of Science ®Google Scholar
• Tomkins O, Berentsen S, Arulogun S, et al. Daratumumab for disabling cold agglutinin disease refractory to B-cell directed therapy. Am J Hematol. 2020;95(10):E293–E295. doi: 10.1002/ajh.25932
   PubMed Web of Science ®Google Scholar
• Khwaja J, Vos JMI, Pluimers TE, et al. Clinical and clonal characteristics of monoclonal immunoglobulin M-associated type I cryoglobulinaemia. Br J Haematol. 2024;204(1):177–185. doi: 10.1111/bjh.19112
   PubMed Web of Science ®Google Scholar
• Khwaja J, Japzon N, Gabriel M, et al. Cold agglutinin disease and cryoglobulinaemia: a frequent coexistence with clinical impact. Br J Haematol. 2023; online ahead of print.204(2). doi: 10.1111/bjh.19185
   Web of Science ®Google Scholar
• Lai JS, Beaumont JL, Ogale S, et al. Validation of the functional assessment of chronic illness therapy-fatigue scale in patients with moderately to severely active systemic lupus erythematosus, participating in a clinical trial. J Rheumatol. 2011;38(4):672–679. doi: 10.3899/jrheum.100799
   PubMed Web of Science ®Google Scholar
• Röth A, Barcellini W, S D, et al. Sutimlimab in cold agglutinin disease. N Engl J Med. 2021;384(14):1323–1334. doi: 10.1056/NEJMoa2027760
   PubMed Web of Science ®Google Scholar
• Röth A, Berentsen S, Barcellini W, et al. Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial. Blood. 2022;140(9):980–991. doi: 10.1182/blood.2021014955
   PubMed Web of Science ®Google Scholar
• Ulvestad E. Paradoxical haemolysis in a patient with cold agglutinin disease. Eur J Haematol. 1998;60(2):93–100. doi: 10.1111/j.1600-0609.1998.tb01004.x
   PubMed Web of Science ®Google Scholar
• Tjønnfjord E, Vengen OA, Berentsen S, et al. Prophylactic use of eculizumab during surgery in chronic cold agglutinin disease. BMJ Case Rep. 2017 May 9;2017:bcr2016219066. doi: 10.1136/bcr-2016-219066
   PubMedGoogle Scholar
• Tvedt THA, Steien E, Øvrebø B, et al. Sutimlimab, an investigational C1s inhibitor, effectively prevents exacerbation of hemolytic anemia in a patient with cold agglutinin disease undergoing major surgery. American J Hematol. 2022;97(2):E51–E54. doi: 10.1002/ajh.26409
   PubMed Web of Science ®Google Scholar
• Perez-Lamas L, Moreno-Jimenez G, Tenorio-Nunez MC, et al. Hemolytic crisis due to covid-19 vaccination in a woman with cold agglutinin disease. Am J Hematol. 2021;96(8):E288–E291. doi: 10.1002/ajh.26214
   PubMed Web of Science ®Google Scholar
• Lyckholm LJ, Edmond MB, Eagle K. Images in clinical medicine. Seasonal hemolysis due to cold-agglutinin syndrome. N Engl J Med. 1996;334(7):437. doi: 10.1056/NEJM199602153340705
   PubMed Web of Science ®Google Scholar
• Fattizzo B, Bortolotti M, Giannotta JA, et al. Intravascular hemolysis and multitreatment predict thrombosis in patients with autoimmune hemolytic anemia. J Thromb Haemost. 2022;20(8):1852–1858. doi: 10.1111/jth.15757
   PubMed Web of Science ®Google Scholar
• Röth A, Bommer M, Hüttmann A, et al. Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial. Blood Adv. 2018;2(19):2543–2549. doi: 10.1182/bloodadvances.2018024190
   PubMed Web of Science ®Google Scholar
• Kamesaki T, Nishimura JI, Wada H, et al. Demographic characteristics, thromboembolism risk, and treatment patterns for patients with cold agglutinin disease in Japan. Int J Hematol. 2020;112(3):307–315. doi: 10.1007/s12185-020-02899-6
   PubMed Web of Science ®Google Scholar
• Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood. 2013;121(25):4985–4996; quiz 5105. doi: 10.1182/blood-2012-09-311381
   PubMed Web of Science ®Google Scholar
• Heurich M, McCluskey G. Complement and coagulation crosstalk - factor H in the spotlight. Immunobiology. 2023;228(6):152707. doi: 10.1016/j.imbio.2023.152707
   PubMed Web of Science ®Google Scholar
• Audia S, Bach B, Samson M, et al. Venous thromboembolic events during warm autoimmune hemolytic anemia. PLoS One. 2018;13(11):e0207218. doi: 10.1371/journal.pone.0207218
   PubMed Web of Science ®Google Scholar
• Berentsen S. How I manage patients with cold agglutinin disease. Br J Haematol. 2018;181(3):320–330. doi: 10.1111/bjh.15109
   PubMed Web of Science ®Google Scholar
• Berentsen S, Tjønnfjord GE. Current treatment options in cold agglutinin disease: B-cell directed or complement directed therapy? Transfus Med Rev. 2022;36(4):36(181–187. doi: 10.1016/j.tmrv.2022.05.001
   Web of Science ®Google Scholar
• Berentsen S, Ulvestad E, Gjertsen BT, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2004;103(8):2925–2928. doi: 10.1182/blood-2003-10-3597
   PubMed Web of Science ®Google Scholar
• Schöllkopf C, Kjeldsen L, Bjerrum OW, et al. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma. 2006;47(2):253–260. doi: 10.1080/10428190500286481
   PubMed Web of Science ®Google Scholar
• Berentsen S, Randen U, Vågan AM, et al. High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. Blood. 2010;116(17):3180–3184. doi: 10.1182/blood-2010-06-288647
   PubMed Web of Science ®Google Scholar
• Rossi G, Gramegna D, Paoloni F, et al. Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study. Blood. 2018;132(5):547–550. doi: 10.1182/blood-2018-03-835413
   PubMed Web of Science ®Google Scholar
• Jalink M, Berentsen S, Castillo JJ, et al. Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. Blood. 2021;138(20):2002–2005. doi: 10.1182/blood.2021012039
   PubMed Web of Science ®Google Scholar
• Jalink M, Jacobs CF, Khwaja J, et al. Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease. Blood Adv. 2024; Online ahaed of print.8(11):2622–2634. doi: 10.1182/bloodadvances.2024012585
   PubMed Web of Science ®Google Scholar
• Tenny S, Varacello M. Evidence based medicine. NIH: National Library of Medicine; 2022; [cited 2024 Apr 13]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470182/
   Google Scholar
• Fadlallah J, Michel M, Crickx E, et al. Bortezomib and dexamethasone, an original approach for treating multi-refractory warm autoimmune haemolytic anaemia. Br J Haematol. 2019;187(1):124–128. doi: 10.1111/bjh.16009
   PubMed Web of Science ®Google Scholar
• Yao M, Zhang J, Li Y, et al. Combination of low-dose rituximab, bortezomib and dexamethasone for the treatment of autoimmune hemolytic anemia. Medicine (Baltimore). 2022;101(4):e28679. doi: 10.1097/MD.0000000000028679
   PubMed Web of Science ®Google Scholar
• El-Ayoubi A, Wang JQ, Hein N, et al. Role of plasma cells in waldenstrom macroglobulinaemia. Pathology. 2017;49(4):337–345. doi: 10.1016/j.pathol.2017.02.004
   PubMed Web of Science ®Google Scholar
• Del Giudice I, Matutes E, Osuji N, et al. Delayed response to fludarabine in lymphoplasmacytic lymphoma/waldenström’s macroglobulinemia. Haematologica. 2005;90(2):268–270.
   PubMed Web of Science ®Google Scholar
• Berentsen S, Barcellini W, D’Sa S, et al. Sutimlimab for treatment of cold agglutinin disease: why, how and for whom? Immunotherapy. 2022;14(15):1191–1204. doi: 10.2217/imt-2022-0085
   PubMed Web of Science ®Google Scholar
• Bartko J, Schörgenhofer C, Schwameis M, et al. A randomized, first-in-human, healthy volunteer trial of sutimlimab, a humanized antibody for the specific inhibition of the classical complement pathway. Clin Pharmacol Ther. 2018;104(4):655–663. doi: 10.1002/cpt.1111
   PubMed Web of Science ®Google Scholar
• Jäger U, D’Sa S, Schörgenhofer C, et al. Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial. Blood. 2019;133(9):893–901. doi: 10.1182/blood-2018-06-856930
   PubMed Web of Science ®Google Scholar
• Gelbenegger G, Jaeger U, Fillitz M, et al. Sustained sutimlimab response for 3 years in patients with cold agglutinin disease: a phase I, open-label, extension trial. Br J Haematol. 2022;198(4). doi: 10.1111/bjh.18289
   PubMed Web of Science ®Google Scholar
• Röth A, Barcellini W, S D, et al. Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease. Am J Hematol. 2023;98(8):1246–1253. doi: 10.1002/ajh.26965
   PubMed Web of Science ®Google Scholar
• Gelbenegger G, Jager U, Fillitz M, et al. Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease. Blood Adv. 2023;7(10):1987–1990. doi: 10.1182/bloodadvances.2022008574
   PubMed Web of Science ®Google Scholar
• Datta SS, Berentsen S. Management of autoimmune haemolytic anaemia in low-to-middle income countries: current challenges and the way forward. Lancet Reg Health Southeast Asia. 2024;23(4):100343. doi: 10.1016/j.lansea.2023.100343
   PubMedGoogle Scholar
• Gertz M, Roman E, Fattizzo B, et al. Inhibition of C3 with APL-2 ControlsHaemolysis and increases haemoglobin levels in subjects with autoimmune haemolytic anaemia (AIHA). Hemasphere. 2019;3(Supplement 1):405. doi: 10.1097/01.HS9.0000561876.96057.48
   Google Scholar
• Hillmen P, Szer J, Weitz I, et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2021;384(11):1028–1037. doi: 10.1056/NEJMoa2029073
   PubMed Web of Science ®Google Scholar
• Zaninoni A, Giannotta J, Galli A, et al. The immunomodulatory effect and clinical efficacy of daratumumab in a patient with cold agglutinin disease. Front Immunol. 2021;12. doi: 10.3389/fimmu.2021.649441
   PubMed Web of Science ®Google Scholar
• Mackness BC, Jaworski JA, Boudanova E, et al. Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life. MAbs. 2019;11(7):1276–1288. doi: 10.1080/19420862.2019.1633883
   PubMed Web of Science ®Google Scholar
• Simmons KT, Chan J, Hussain S, et al. Anti-C1s humanized monoclonal antibody SAR445088: a classical pathway complement inhibitor specific for the active form of C1s. Clin Immunol. 2023;251(109629):109629. doi: 10.1016/j.clim.2023.109629
   PubMedGoogle Scholar
• D’Sa SP, Vos JMI, Barcellini W, et al. Safety, tolerability and activity of the active C1s antibody riliprubart in cold agglutinin disease: a Phase 1b study. Blood. 2023;143(8):713–720. doi: 10.1182/blood.2023022153
   Web of Science ®Google Scholar
• Lansita JA, Mease KM, Qiu H, et al. Nonclinical development of ANX005: a humanized anti-C1q antibody for treatment of autoimmune and neurodegenerative diseases. Int J Toxicol. 2017;36(6):449–462. doi: 10.1177/1091581817740873
   PubMed Web of Science ®Google Scholar
• Gertz MA, Qiu H, Kendall L, et al. ANX005, an inhibitory antibody against C1q, blocks complement activation triggered by cold agglutinins in human disease. 58th meeting of the american society of hematology, San Diego, CA, USA. Blood. 2016;128:1265. doi: 10.1182/blood.V128.22.1265.1265
   Web of Science ®Google Scholar
• Van de Walle I, Silence K, Budding K, et al. ARGX-117, a therapeutic complement inhibiting antibody targeting C2. J Allergy Clin Immunol. 2021;147(4):1420–1429 e1427. doi: 10.1016/j.jaci.2020.08.028
   PubMed Web of Science ®Google Scholar
• Hummingbird-Bioscience. Hummingbird bioscience to present preclinical proof of concept for potentially first-in-class antibody targeting autoimmune diseases. [cited 2024 Feb 8]. Available from: https://www.prnewswire.com/news-releases/hummingbird-bioscience-to-present-preclinical-proof-of-concept-for-potentially-first-in-class-antibody-targeting-autoimmune-diseases-301817891.html.2023
   Google Scholar
• Evans LS, Lewis KE, DeMonte D, et al. Povetacicept, an enhanced dual APRIL/BAFF Antagonist that modulates b lymphocytes and pathogenic autoantibodies for the treatment of lupus and other B cell-related autoimmune diseases. Arthritis Rheumatol. 2023;75(7):1187–1202. doi: 10.1002/art.42462
   PubMed Web of Science ®Google Scholar
• Samy E, Wax S, Huard B, et al. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. Int Rev Immunol. 2017;36(1):3–19. doi: 10.1080/08830185.2016.1276903
   PubMed Web of Science ®Google Scholar
• Broome C, Kuter DJ, McCrae KR, et al. Initial report of povetacicept, an enhanced dual BAFF/APRIL antagonist, in autoimmune cytopenias: the RUBY-4 study. Blood. 2023;142(Supplement 1):5520. doi: 10.1182/blood-2023-179305
   Google Scholar
• Berentsen S. Cold agglutinins: fending off the attack. Blood. 2019;133(9):885–886. doi: 10.1182/blood-2019-01-894303
   PubMed Web of Science ®Google Scholar
• Grillo-Lopez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol. 1999;26(5 Suppl 14):66–73.
   PubMed Web of Science ®Google Scholar
• Das SS, Das S, Shastry S, et al. Real-world data from India on clinical practices in the management of autoimmune haemolytic anaemia: a survey-based cross-sectional assessment. Transfus Clin Biol. 2023;30(1):137–142. doi: 10.1016/j.tracli.2022.09.069
   PubMed Web of Science ®Google Scholar
• Mulder FVM, Evers D, de Haas M, et al. Severe autoimmune hemolytic anemia; epidemiology, clinical management, outcomes and knowledge gaps. Front Immunol. 2023;14(1228142). doi: 10.3389/fimmu.2023.1228142
   Google Scholar